Dr. Shune continues the case discussion by describing disease progression following second-line therapy and outlining her approach to third-line treatment selection in cGVHD. After initiating systemic ...

Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS-mutated mCRC. Cardiff Oncology plans a registrational trial to compare ...

BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important predictive ...

The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including ...

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

Crohn’s disease is a type of inflammatory bowl disease (IBD) that can take place anywhere in the digestive tract. According to the Centers for Disease Control and Prevention (CDC), prevalence of IBD ...

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...